NASDAQ:CDIO

Cardio Diagnostics Q1 2026 Earnings Results & Report

Cardio Diagnostics logo
$1.60 -0.05 (-3.03%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.60 -0.01 (-0.31%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardio Diagnostics reported Q1 2026 earnings on May 15, 2026. The company reported EPS of -$0.63.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes

Cardio Diagnostics EPS Results

Actual EPS
-$0.63
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 5 quarters

Cardio Diagnostics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Cardio Diagnostics Q1 2026 Earnings FAQ

Cardio Diagnostics (NASDAQ:CDIO) reported earnings of -$0.63 per share for Q1 2026. The report was announced on Friday, May 15, 2026.

Cardio Diagnostics Earnings Headlines

Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
See More Cardio Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardio Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardio Diagnostics and other key companies, straight to your email.

About Cardio Diagnostics

Cardio Diagnostics (NASDAQ:CDIO) develops blood-based tests and technology for cardiovascular disease assessment. Its platform combines genetic and epigenetic information with artificial intelligence to support more personalized evaluation of heart disease.

The company’s offerings include Epi+Gen CHD, designed to assess a person’s risk of coronary heart disease, and PrecisionCHD, a test intended to help identify coronary heart disease in people being evaluated for the condition. The tests are designed to complement clinical assessment and are not a substitute for care from a health professional.

Founded in 2017 and based in Chicago, Illinois, Cardio Diagnostics was co-founded by Meesha Dogan, who serves as its chief executive officer. The company focuses primarily on making its testing services available in the United States.

View Cardio Diagnostics Profile